CVS Health Corporation (CVS) Analyst Ratings & Price Targets

CVS Health Corporation

CVS · NYSE

Analyst Consensus

Buy

23 analysts

$97

Current

—

Low

$115

Average

—

High

Average target implies +18.36% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 23 analysts, with a mean price target of $113.50. No low or high target is reported, so the target spread and the degree of clustering cannot be measured; the mean is the only stated reference point. The evidence does not identify the most bullish or least bullish analyst, any named brokerage, or target revisions during the past week. It therefore cannot establish whether revisions were moving higher or lower. The substantive disagreement behind the target range is also unavailable, although the broader evidence frames the key debate as whether earnings beats and Aetna-led growth can continue.

Rating Actions

No individual rating actions have been captured for CVSyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

CANTOR FITZGERA

CO FORECST

DEUTSCHE BK SEC

EDWARD JONES

EVERCORE ISI

GOLDMAN SACHS

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

MIZUHO SECURITI

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

WOLFE RESEARCH

Symbol: CVS
Type: Stock
Sector: Consumer Staples
Industry: Retail-Drug Stores and Proprietary Stores
Country: North America
Exchange: NYSE

CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of June 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Key Issues

Bullish view

CVS delivered a 37.97% earnings surprise and a 5.91% revenue surprise for the quarter ended June 2026, while RTTNews reported that quarterly profit increased year over year. That performance supports the view that the company can continue exceeding estimates.

Bearish view

One quarterly beat does not establish a durable trend, particularly because the supplied evidence gives no detail on the sources or quality of the profit increase. Investors still need to assess whether the improvement can persist after the earnings release.

Analyst Consensus

See all

Buy

23 analysts

$97

Current

—

Low

$115

Average

—

High

Average target implies +18.36% versus the current price.

Earnings History

BeatMissNo estimate

CVS Health Corporation

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers